Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killing.

Ferrari, Valentina; Tarke, Alison; Fields, Hannah; Tanaka, Tiffany N; Searles, Stephen; Zanetti, Maurizio

Ferrari, Valentina; Tarke, Alison; Fields, Hannah; Tanaka, Tiffany N; Searles, Stephen; Zanetti, Maurizio.

Afiliação

Ferrari V; PersImmune, Inc., San Diego, CA, United States.
Tarke A; PersImmune, Inc., San Diego, CA, United States.
Fields H; PersImmune, Inc., San Diego, CA, United States.
Tanaka TN; Moores Cancer Center, Department of Hematology and Oncology, University of California San Diego, La Jolla, CA, United States.
Searles S; The Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Zanetti M; The Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, United States.

Front Oncol ; 12: 915629, 2022.

Article em En | MEDLINE | ID: mdl-35992887

Palavras-chave

adoptive cell transfer (ACT); immune check inhibitor (ICI); myelodyslastic syndromes; neoantigens (neoAgs); unfolded protein response (UPR)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article